| |
Newsroom /
Medical
/
Medical
/
Indian Immunodiagnostics Market to Grow at a CAGR of 11% in the Next Five Years
Indian Immunodiagnostics Market to Grow at a CAGR of 11% in the Next Five Years
Driven by factors such as increasing popularity in preliminary testing, portability and ease of use; the market for Immunodiagnostics is expected to grow robustly in the coming years.
Noida,
Uttar pardesh,
India
(prbd.net)
06/02/2012
IMARC Group, one of the world's leading research and advisory firms, in its latest report entitled “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” expects the market for immunodiagnostics in India to grow at a CAGR of 11% during 2011-16. Findings from the report suggested that immunology based diagnostics currently provide numerous advantages over other diagnostic technologies. The time, duration and costs currently involved with immunodiagnostics, and in particular, the rapid tests are ideal for conducting preliminary tests. Immunology based tests offer a significantly higher sensitivity compared to microscopy based tests and are significantly more economical and easier to use than the PCR based tests which are currently mainly used as confirmatory tests. Apart from their popularity in preliminary testing, the report also found that most rapid immunodiagnostic tests also offer other advantages such as portability and ease of use. Some of the rapid tests are highly portable and can be easily conducted anywhere without the requirements of sophisticated labs, equipment, electricity or trained technicians. For instance, around 70% of the total pregnancy tests are currently being conducted at home without the requirement of a lab or a trained technician.
Despite its strong growth, the report also noted that factors such as decreasing prices, short product lifecycles and high dependency on imports were major factors hampering the growth of this market. The report found that a major cause of concern was the increasing imports from China, with Chinese manufacturers selling their kits at significantly lower prices than that of domestic manufacturers.
IMARC’s new report entitled “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” provides an analytical and statistical insight into the Indian Antibodies market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of the following aspects of the Indian antibodies market.
Key Aspects Analyzed:
Diagnostic Antibodies
Understanding the strengths, weaknesses, opportunities and challenges in the Indian diagnostic antibodies market
Understanding the technological considerations and regulatory factors in the Indian diagnostic antibodies market
• Evaluating the various types of antibody based diagnostic tests conducted in India and analyzing their strengths and weaknesses.
• Understanding the key regulations for registering, manufacturing and importing diagnostics in India.
Comprehensive situation analysis of the Indian diagnostic antibodies market
Segments covered: HIV, Hepatitis B, Hepatitis C, Tuberculosis, Dengue, Syphilis and Oncology
Focus of the analysis in each segment:
• Number of tests conducted each year
• Breakup by type of tests conducted
• Current and future market sales
• Average cost of diagnostic tests
• Key players operating in the market
Therapeutic Antibodies
Understanding the strengths, weaknesses, opportunities and challenges in the Indian therapeutic antibodies market
Understanding the technological considerations and regulatory factors in the Indian therapeutic antibodies market
• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act.
• Understanding the key regulations for registering, manufacturing and importing therapeutic antibodies in India.
Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe.
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe.
Comprehensive situation analysis of the Indian therapeutic antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroa
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/
About
For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
|